Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

Análisis de la interacción entre los genes FTO e IRX3 con obesidad y desórdenes metabólicos relacionados en una población mixta de América Latina: un posible aumento del riesgo de exceso de peso

María Stehpany Ruiz-Díaz,1,2 Diana Mena-Yi,1 Doris Gómez-Camargo,1 Gustavo Mora-García1

gmorag@unicartagena.edu.co

1 Universidad de Cartagena, Facultad de Medicina. Cartagena de Indias, Colombia, 2 Centro de Innovación e Investigación en Metabolismo y Diabetes - Innovatid-. Cartagena de Indias, Colombia.

Abstract

Background:
Fat Mass and Obesity-related (FTO) has been one of the genes consistently related to common obesity. Single nucleotide polymorphisms (SNPs) in FTO have been linked with the IRX3 gene.

Aim:
This study was designed by testing the hypothesis that: i) common SNPs in FTO and IRX3 are associated with obesity and related disorders; ii) there is significant linkage disequilibrium between both genes.

Methods:
A cross-sectional study was carried out on the Colombian Caribbean Coast. Anthropometric and biochemical variables were measured, and obesity and metabolic disorders were diagnosed. Four SNPs were genotyped: 3 at FTO locus (rs17817449, rs8050136, rs9939609) and one at IRX3 locus (rs3751723). LD between these SNPs was estimated. A logistic regression model was applied to estimate associations.

Results:
A total of 792 subjects were included. FTO and IRX3 were not in LD (D'≤ 0.03; R2≤ 0.03). TT genotype (rs9939609) was found to be associated with waist circumference (p= 0.04; adj-p= 0.01), and IRX3 SNP with Body Weight Excess (BWE) (OR= 1.06, adj-p= 0.03). One FTO-IRX3 haplotype was associated with BWE (G-A-A-T, rs17817449-rs8050136-rs9939609-rs3751723; OR= 0.67, p= 0.04). The statistical significance of these relations continued after admixture adjustment for a three-hybrid population (p= 0.03).

Conclusions:
FTO was related to waist circumference, and IRX3 was associated with BWE in Latin American adults. This relation remained statistically significant after an adjustment for sex, age, and genetic ancestry was performed. Despite that these genes were not in LD, findings of a haplotype involving FTO-IRX3 suggest a gene-gene interaction associated with an increased risk of BWE.
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

Conflicts of interest:
Nothing

Funding:
This work was supported by Vicerrectoría de Investigaciones, Octava convocatoria para la financiación de proyectos de investigación (Res 02565 de 2016) Colombia. M.S. Ruiz-Díaz was supported by the Colombian Ministry of Science, Technology, and Innovation (MINCIENCIAS) by resolution no. 2286, 2015.

Corresponding author:
Gustavo Mora-García Campus de Zaragocilla, Edificio Facultad de Medicina, Cartagena de Indias, Bolívar, Colombia. Postal code: 130012. Phone/Fax: 1 (443) 362-0110. E-mail: gmorag@unicartagena.edu.co

Resumen

Introducción:
FTO (Fat Mass and Obesity-related) se ha relacionado de manera consistente con la obesidad. Recientemente, Polimorfismos de Nucleótido Único (SNP) en este gen se han relacionado con el gen IRX3.

Objetivo:
Probar la hipótesis de que: i) SNPs en FTO e IRX3 están asociados con la obesidad y trastornos relacionados; ii) existe desequilibrio de ligamiento (LD) significativo entre ambos genes.

Métodos:
se realizó un estudio transversal en la costa caribe colombiana. Se valoraron variables antropométricas y bioquímicas, la obesidad y trastornos metabólicos. Se genotipificaron 4 SNPs: 3 en FTO (rs17817449, rs8050136, rs9939609) y uno en IRX3 (rs3751723). Se estimó el LD entre estos SNPs. Se aplicó un modelo de regresión logística para estimar asociaciones.

Resultados:
Se incluyeron 792 sujetos. FTO e IRX3 no se encontraron en LD (D’ ≤0.03; R2 ≤0.03). El genotipo TT (rs9939609) se encontró asociado con la circunferencia de la cintura (p= 0.04; adj-p= 0.01), y el SNP IRX3 con el Exceso de Peso (EP) (OR= 1.06, adj-p= 0.03). Se encontró un haplotipo FTO-IRX3 asociado con EP (G-A-A-T, rs17817449-rs8050136-rs9939609-rs3751723; OR= 0.67, p= 0.04). Esta asociación persistió después del ajuste para una población mixta (p= 0.03).

Conclusiones:
FTO se encontró asociado con la circunferencia de la cintura e IRX3 con EP en adultos latinoamericanos. Estas asociaciones persistieron tras el ajuste por sexo, edad y ascendencia genética. Aunque estos genes no estaban en LD, los hallazgos de un haplotipo entre FTO-IRX3 sugieren una interacción gen-gen asociada con un mayor riesgo de EP.
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

Remark

1) Why was this study conducted?

The Latin American population has been exposed to significant racial mixing. In mixed populations such as this, understanding the genotype/phenotype interactions behind complex diseases such as obesity and obesity-related diseases remains a challenging task because genetic stratification represents a source of confounding bias. However, the diversity in this type of population is also an opportunity to discover associated genetic factors that could be useful in understanding complex diseases such as obesity. The present study provides evidence by testing the hypothesis that common Single Nucleotide Polymorphisms (SNPs) in FTO and IRX3 genes are associated with obesity and metabolic syndrome-related disorders; and that there is a significant interaction between both genes, when tested in a Latin American population in which a tri-hybrid genetic mixture has been previously described.

2) What were the most relevant results of the study?

Genetic variants in FTO gene were found to be unrelated to obesity or body weight, metabolic disorders (i.e., hypertension, hyperglycemia, dyslipidemias, type 2 diabetes mellitus), and metabolic syndrome. On the other hand, IRX3 gene was found to be associated with excess body weight even after adjustment for genetic stratification.

3) What do these results contribute?

The findings of the current study showed no evidence of nonrandom segregation between the FTO and IRX3 SNPs in this sample of Latin American adults, possibly associated with the genetic substructure and the recent admixture process, which could be interfering with the measurement of intergenic applications. However, the design of other studies aimed at describing the role of the IRX3 gene and its product in energy metabolism appear to hold promise in understanding the real epidemic of excess body weight in populations with high genetic diversity.

Introduction

Obesity is a public health priority in almost every region worldwide. Its prevalence has continuously increased during the last three decades, shaping an epidemic pattern that has negatively impacted high-, middle- and low-income communities. As obesity prevalence increases, so do the frequency of metabolic disorders (e.g., dyslipidemias and high blood pressure, etc.), which share some pathophysiologic pathways.

Genetic factors have been widely identified to be involved in obesity and the pathogenesis of obesity-related diseases, such as Diabetes Mellitus type 2, dyslipidemia, hypertension, and cardiovascular disease. Among these, the Fat Mass and Obesity-related (FTO) has been one of the genes most consistently related to common obesity, according to findings from many Genome-Wide Association Studies (GWAS). FTO gene plays an important role in regulating appetite and energy homeostasis. In addition, some allelic variants have been strongly associated with fat deposition. Despite that, the role of variations in the FTO chromosomal region and the protein FTO (a nuclear demethylase) on the cellular mechanisms responsible for the development of obesity has not been completely described.

Recent studies have shown that some allelic variants in FTO first intron might be influencing the transcription regulation of genes located near loci. In this regard, Smemo et al., and other authors have uncovered long-range functional connections between FTO first intron variants and the expression of the Iroquois Homeobox 3 (IRX3) gene. Furthermore, there is increasing...
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

Evidence that epistasis may play a role in disease risk, thus, the analysis of the relationship between these two genes could be particularly promissory since the activity of the IRX3 protein has been associated with appetite control and obesity phenotype in animals.

The Latin American population has been exposed to more significant racial admixture. In admixed populations like this, understanding the genotype/phenotype interactions behind complex diseases such as obesity and obesity-related diseases remains a challenging task because genetic stratification represents a source of bias brought about by confounding phenomena. However, the diversity in this type of population is also an opportunity to uncover associated genetic factors that might be helpful to understanding complex diseases such as obesity.

Based on those previous findings, some studies have been developed to analyze plausible linkage disequilibrium between FTO and IRX3 SNPs. Altogether, these results have revealed that this genomic interaction could be identified at the population level, which contributes to understanding the mechanisms of genetic predisposition to obesity and how genetic factors influence the current epidemic. Hence, the present study was designed to add evidence by testing the hypothesis that i) common SNPs in FTO and IRX3 are associated with obesity and related disorders; ii) there is significant interaction between both genes. These hypotheses were tested on a Latin American population in which a tri-hybrid genetic admixing has been previously described.

Materials and Methods

Subjects

A cross-sectional study was carried out in Cartagena de Indias, a 1-million inhabitants city located on the Colombian Caribbean Coast. A sample of 792 subjects was employed to achieve 80% power of discrimination of genetic association with 2.5/3.5 (heterozygotes/homozygotes) odds ratio, assuming an outcome with 25% prevalence, 25% minor allele frequency, complete linkage disequilibrium (D’ = 1), and 5% alpha-coefficient, according to calculations described by other authors, and as was applied in a previous work. Genetic Power Calculator software (http://zzz.bwh.harvard.edu/gpc/cc2.html) was used for this calculation.

Inclusion criteria included non-sibling subjects from both genders aging more than 18 years old who live in urban areas of Cartagena de Indias, a city located on the Colombian Caribbean Coast (an admixed population with a predominant European ancestry (~60%) due to Spaniard’s colonization between XVI and XIX centuries). Siblings were initially identified by surnames comparison and then confirmed by telephone; therefore, first- and second-degree siblings were excluded for the analysis.

Those suffering from diseases that affect their body weight as primary endocrine disorders, genetic pathology, cancer, or surgical obesity treatment, as well as pregnant or breastfeeding, were also excluded. All subjects gave their informed consent to participate in the study, following the University of Cartagena ethics committee considerations. Subjects with missing data were excluded.

Participants were enrolled by trained medical staff in charge of performing an interview and physical examination focused on sociodemographic and clinical variables and the medical record of metabolic-related disorders (Figure 1).

Anthropometric variables

During the physical examination, anthropometric data were obtained. Height, weight, and waist circumference were recorded; all these measurements were obtained according to international diabetes guidelines for metabolic syndrome described by World Health Organization (WHO). Height was measured in meters (m) using a stadiometer with the subject barefoot and straight. Weight was recorded in kilograms (Kg) through a calibrated bascule with the participant wearing light clothes without shoes. Body mass index (BMI)
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

was calculated by dividing weight in Kg between the square of the height in meters (m$^2$). An inelastic metric tape was used to measure the waist and hip circumference with a patient in a standing position, ensuring that the tape did not compress the skin. Blood pressure was measured using a sphygmanomanometer following the 8th Joint National Committee (JNC8) 22.

**Biochemical analysis.** A whole-blood sample was collected from each one of the participants, who should have a fast of at least 8 hours. Serum concentrations of glucose, triglycerides (TG), and HDL cholesterol (HDLc) were measured through colorimetric assays at the UNIMOL laboratory at the University of Cartagena, following standard protocols.

**Obesity and metabolic traits**

Obesity was defined using the cut-off points for BMI suggested by the WHO 21,23. Bodyweight excess (BWE) was defined as either overweight or obesity.

- Normal weight: BMI >18.5 and <25 Kg/m$^2$
- Overweight: BMI ≥25 and <30 Kg/m$^2$
- Obesity: BMI ≥30 Kg/m$^2$
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

Hypertension or High Blood Pressure (HBP) was determined according to JNC8:

- Adults <60 years old: systolic ≥ 140 mmHg, diastolic ≥ 90 mmHg
- Adults ≥60 years old: systolic ≥ 150 mmHg, diastolic ≥ 90 mmHg

Metabolic syndrome and related conditions were defined through the Joint Interim Statement (JIS) criteria, considering the criteria described elsewhere.

- Abdominal obesity: waist circumference in men ≥ 90 cm and women ≥ 80 cm.
- Hyperglycemia: glucose impaired fasting ≥ 100 mg/dl or drug treatment for elevated glucose

Diabetes was determined through the American Diabetes Association (2018) criteria, considering the presence of the disease with fasting blood glucose values > 126 mg/dL or by HbA1c values ≥ 6.5%.

Genotyping

Common variants in FTO and IRX3 were identified using 1,000 genome project reports. For this purpose, the bioinformatic resource SNiPA was used. SNPs with a minor allele frequency (MAF) ≥ 0.25 and correlation coefficient (R²) = 1.0 were selected using data from populations with European ancestry. With this procedure, 3 variants were selected for FTO: rs9939609 (c.46-23525T>A), rs8050136 (c.46-27777C>A), rs17817449 (c.46-30685T>G) and only one for IRX3: rs3751723 (c.-235C>A), based on previous reports where the linkage disequilibrium between both genes was analyzed. These variants are proxies for several variants and have shown antecedents of genetic association with metabolic traits and obesity-related diseases.

SNPs were genotyped with quantitative polymerase chain reaction (qPCR) using Taqman probes (Thermo Fisher Scientific, Inc., Waltham, MA, USA). In addition, allelic discrimination and data were analyzed by StepOne Real-Time PCR Software (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Statistics

Sociodemographic, anthropometric, biochemicals, and the other metabolic variables were described using the central tendency and frequency values as necessary, and the Lilliefors test was realized to verify the normality. Finally, mean values were compared using t-test and frequencies with Ji² or Fisher's exact test.

Allelic and genotype frequencies were described through direct count. Hardy-Weinberg Equilibrium was assessed through the inbreeding coefficient (Fis) values using Genetix 4.05 software. Linkage disequilibrium between the selected SNPs was estimated with the package genetics for R program 3.5.0; D' (D prime) and R² (R-square) were reported.

Associations between continuous traits and genotype distributions were analyzed using the analysis of variance (ANOVA) or the Kruskal Wallis test, where appropriate. Relations between categorical variables (metabolic traits), were determined with Ji².

Additive genotype models were evaluated using generalized regression models. Haplotype models were also performed to estimate the association between FTO and IRX3 SNPs with obesity and related outcomes. These models were adjusted by age, sex, and BMI, except for the bodyweight excess (overweight and obesity) analyses, where this last variable (BMI) was not employed due to collinearity. R program version 3.5.0, with the genetics and PredictABEL packages, was employed.
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

Associations were adjusted by genetic stratification assuming a three-hybrid substructure (k= 3) using a Bayesian approach (Markov Chain Monte Carlo, or MCMC) with 100,000 replications using the STRAT software version 1.1 for DOS/Windows.

The three-hybrid admixture pattern applied is based on previous reports from Cartagena de Indias, where informative ancestry markers (AIMs) and the Y chromosome were used to describe local genetic substructure and ancestry distribution. In this study, 17 Y chromosome short tandem repeats (Y-STR; AmpFLSTR Yfiler® PCR Amplification Kit, Thermo Fisher, Inc., USA) were used to confirm the admixture in sampled males.

**Results**

**General data**

A total of 805 subjects were enrolled out, 13 were excluded (Figure 1). Finally, registers of 792 subjects (55.7% men and 44.3% women) were used in further analyses. The median age was 36 IQR: (28;52) years. Age ranges of included individuals were distributed according to population pyramid.

**Anthropometric and serum biochemical variables**

Median values for height, weight and BMI were 1.66 m IQR: (1.60;1.73), 71.3 Kg IQR: (60.7;81.5) and 25.6 Kg/m² IQR: (22.7;28.6), respectively. For the abdominal circumference median was 92 cm IQR: (84;99). Regarding blood pressure, the median values for systolic and diastolic pressure were 110 mmHg IQR: (110-120) and 74 mmHg IQR: (70;80) respectively.

Respecting biochemical variables, the median value for glycemia was 89.4 IQR: (78.6;104.4), serum concentration of triglycerides was 151.1 mg/dL IQR: (113.9;187.8), of HDL cholesterol was 46.0 mg/dL IQR: (39.2-51.8) and of total cholesterol was 183.3 mg/dL IQR: (160.4;205.4).

**Metabolic traits**

About 56.8% (n= 450/792) of general population had excess of weight; Among this, 39.7% (n= 315/792) had overweight and the 17.1% (n= 135/792) had obesity.

HBP was found in 13.7% (n= 109/792) of total sample. The frequency of hyperglycemia was 32.0% (n= 254/792), and 17.1% (n= 136) was diagnosed with type 2 Diabetes Mellitus (Glycemia ≥126 mg/dL, or drug treatment). More than a half of individuals had high serum concentrations of triglycerides (50.8%, n= 403/792), 43.5% (n= 345/792) low concentrations of HDL cholesterol and 38.7% (n= 307/792) had high serum concentrations of total cholesterol. Metabolic syndrome was diagnosed in 31.9% (n= 253/792) of population.

**Genotyping**

Genotyping assays were performed on the 792 subjects. Genotype distribution and F values for Hardy-Weinberg equilibrium are shown in Table 1.

**Linkage Disequilibrium: association between alleles**

FTO gen SNPs (rs9939609, rs17817449 and rs8050136) were not in LD with IRX3 gen SNP (rs3751723) (D'≤0.03; R² ≤0.03).

**Genetic associations**

Anthropometric variables were described through median and frequency values and were compared according to genotype distributions. In the FTO gene, for HDL cholesterol, TT homozygotes (rs9939609) shown lower values in comparison with AT+AA genotype (p= 0.037), CC homozygotes (rs8050136) unlike AC+AA genotypes (p=0.049), and TT allele unlike GG+TT genotype (p= 0.036) (Table 2). The statistical association between metabolic alterations and genotypes was not found (Table 3).
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

In the regression models where all SNPs were included as variables, TT genotype (rs9939609) was found to be associated with waist circumference ($p = 0.04$; adj-$p = 0.01$). IRX3 SNP was found to be associated with BWE (OR= 1.06, adj-$p = 0.03$) (Table 4). Also, one FTO-IRX3 haplotype was found to be associated with BWE (G-A-A-T, rs17817449-rs8050136-rs9939609-rs3751723; OR= 0.67, $p = 0.04$).

The additive model showed a significant association between excess weight and the SNP rs3751723 in IRX3 gen (OR= 1.06, $p = 0.024$), taking “G” as the risk allele. The statistical significance of these relations continued after admixture adjustment for a three-hybrid population ($p = 0.03$) (Table 4). However, an additional analysis was performed, and statistical significance was not found (Table 5).

**Discussion**

In the current study, FTO and IRX3 variations were assessed to find a genetic association with obesity and related disorders. Also, linkage disequilibrium between both genes was analyzed. According to our results, genetic variants in FTO were found to be unrelated to obesity or body weight, metabolic disorders (i.e., HBP, Hyperglycemia, dyslipidemias, type 2 Diabetes Mellitus,) and metabolic syndrome. On the other hand, IRX3 was found to be associated with body weight excess even after the adjustment by genetic stratification. Furthermore, despite previous reports, both genes were found to be in linkage equilibrium in this Latin American admixed population.

Table 1. Allelic frequencies and genotype distributions for FTO and IRX3 genes

| Gene                      | n   | (%) | $F_{is}$ | $p$   |
|---------------------------|-----|-----|----------|-------|
| **FTO**                   |     |     |          |       |
| rs9939609 (c.46-23525T>A) |     |     |          |       |
| A                         | 497 | (31.4) | 0.09 | 0.134 |
| T                         | 1087 | (68.6) |     |       |
| AA                        | 89  | (11.2) |     |       |
| AT                        | 319 | (40.3) |     |       |
| TT                        | 384 | (48.5) |     |       |
| rs8050136 (c.46-27777C>A) |     |     |          |       |
| A                         | 481 | (30.4) | 0.08 | 0.205 |
| T                         | 1103 | (69.6) |     |       |
| AA                        | 83  | (10.5) |     |       |
| AC                        | 315 | (39.8) |     |       |
| CC                        | 394 | (49.7) |     |       |
| **rs17817449 (c.46-30685T>G)** | | | | |
| G                         | 466 | (29.4) | 0.08 | 0.262 |
| T                         | 1118 | (70.6) |     |       |
| GG                        | 78  | (9.9) |     |       |
| GT                        | 310 | (39.1) |     |       |
| TT                        | 404 | (51.0) |     |       |
| **IRX3**                  |     |     |          |       |
| rs3751723 (c.-235C>A)     |     |     |          |       |
| T                         | 394 | (24.9) | 0.04 | 0.09  |
| G                         | 1190 | (75.1) |     |       |
| TT                        | 55  | (7.0) |     |       |
| GG                        | 453 | (57.2) |     |       |
| GT                        | 284 | (35.8) |     |       |

$F_{is}$: inbreeding coefficient.
### Table 2. Median values of anthropometric and biochemistry parameters according to the genotype for FTO and IRX3 SNPs.

| FTO  | BMI (Kg/m²) | Waist Circ. (cm) | Blood Pressure | Serum concentrations | Triglycerides | HDLc | Totalc |
|------|-------------|-----------------|----------------|----------------------|---------------|------|--------|
| AA   | 25.3        | 88.0            | 110.0          | 89.1                 | 68.1          | 46.3 | 175.9  |
| AT   | 25.4        | 89.0            | 111.0          | 89.1                 | 68.1          | 46.3 | 175.9  |
| TT   | 25.4        | 89.0            | 111.0          | 89.1                 | 68.1          | 46.3 | 175.9  |

The prevalence of body weight excess was associated with IRX3. A 10% increase in overweight or obesity frequency was found when rs3751723 genotype changed from GG to TT. This result coincides with recent studies from multiple populations in which the IRX3 genomic region has been related to anthropometric traits and obesity. Considering that this gene has been identified as a plausible effector for the influence of FTO on body weight, the current genetic associations might be evidence supporting the biological role of FTO and IRX3 on weight control as it has been suggested in animal models.

It is important to note that most Latin American communities are experiencing an intense nutrition transition. Under this phenomenon, a large proportion of inter-personal variability of BMI would be influenced by social and economic factors, such as urbanization and income, among others. It is plausible that the influence of socio-economic variables could have attenuated the impact of FTO genetic variations on the susceptibility to obesity. Similar interactions have been seen in other studies where the effect size and statistical significance are modified by environmental factors (e.g., dietary behaviors).
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

| Tabla 3. Allelic frequencies and genotype distributions for FTO and IRX3 genes |
|-------------------------|-----------------|-----------------|
|                         | rs9939609       | rs8050136       | rs17817449      |
| Gene                    | AA | AT | TT | p | AA vs AT+TT | TT vs A T+AA | AA | AC | CC | p | AA vs AC+CC | CC vs AC+AA | GG | GT | TT | p | GG vs GT+TT | TT vs GT+GG |
|-------------------------|-----------------|-----------------|-----------------|
| **Anthropometric and biochemical parameters** |
| BMI                      |                |                |                |
| Normal weight            | 40 (44.9)      | 148 (46.4)     | 154 (40.1)     |
| Overweight               | 32 (36.0)      | 123 (38.6)     | 160 (41.7)     |
| Obese                    | 17 (19.1)      | 48 (15.0)      | 70 (18.2)      |
| Excess of weight         | 49 (55.1)      | 171 (43.6)     | 230 (59.9)     |
| WC                       |                |                |                |
| Abdominal Obesity        | 59 (66.3)      | 215 (67.4)     | 282 (73.4)     |
| Not altered              | 30 (33.7)      | 104 (32.6)     | 102 (26.6)     |
| BP                       |                |                |                |
| HBP                      | 14 (15.7)      | 46 (14.4)      | 49 (12.7)      |
| Not altered              | 75 (84.3)      | 273 (85.6)     | 335 (87.3)     |
| Serum glucose            |                |                |                |
| Hyperglycemia            | 24 (27.0)      | 111 (34.8)     | 119 (30.0)     |
| Not altered              | 65 (73.0)      | 208 (65.2)     | 265 (70.0)     |
| Serum TG                 |                |                |                |
| HyperTG                  | 44 (49.4)      | 164 (51.4)     | 195 (50.8)     |
| Not altered              | 45 (50.6)      | 155 (48.6)     | 189 (49.2)     |
| Serum HDLc               |                |                |                |
| Low HDLc                 | 43 (48.3)      | 130 (40.8)     | 127 (44.8)     |
| Not altered              | 46 (51.7)      | 189 (59.2)     | 212 (55.2)     |
| TC                       |                |                |                |
| Hight TC                 | 59 (33.7)      | 188 (41.1)     | 238 (38.0)     |
| Not altered              | 30 (66.3)      | 131 (58.9)     | 146 (62.0)     |
| MetS                     |                |                |                |
| Yes                      | 27 (30.3)      | 100 (31.3)     | 126 (38.2)     |
| No                       | 62 (69.7)      | 219 (68.7)     | 258 (68.2)     |
| Diabetes                 |                |                |                |
| Yes                      | 13 (14.6)      | 59 (18.5)      | 64 (16.7)      |
| No                       | 76 (85.4)      | 260 (81.5)     | 320 (83.3)     |

Data are numbers (%). *p < 0.05. Abbreviations: Abd. obesity - abdominal obesity, BMI - body mass index, HDLc - high-density lipoprotein cholesterol, HyperTG - hypertriglyceridemia, MetS - metabolic syndrome, TG - triglycerides, WC - waist circumference.
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

**Table 4.** Association of FTO and IRX3 genes variants with metabolic disorders

| Metabolic traits | rs9939609 | rs8050136 | rs17817449 | rs3751723 |
|------------------|-----------|-----------|------------|-----------|
|                  | Beta coef. | OR        | 95% CI     | p*        | Adjusted p | Beta coef. | OR        | 95% CI     | p*        | Adjusted p | Beta coef. | OR        | 95% CI     | p*        | Adjusted p | Beta coef. | OR        | 95% CI     | p*        | Adjusted p |
| Weight excess    | -0.036     | 0.96      | 0.91-1.01  | 0.156     | 0.225      | -0.026     | 0.97      | 0.92-1.02  | 0.319     | 0.363      | -0.036     | 0.96      | 0.91-1.01  | 0.167     | 0.194      | -0.036     | 0.96      | 0.91-1.01  | 0.167     | 0.194      |
| Abd. Obesity     | -0.043     | 0.95      | 0.91-1.00  | 0.068     | 0.346      | -0.035     | 0.96      | 0.92-1.01  | 0.141     | 0.152      | -0.037     | 0.96      | 0.91-1.01  | 0.123     | 0.131      | -0.007     | 0.99      | 0.94-1.04  | 0.764     | 0.057      |
| HBP              | 0.015      | 1.01      | 0.98-1.05  | 0.394     | 0.124      | 0.024      | 1.02      | 0.98-1.06  | 0.175     | 0.076      | 0.011      | 1.01      | 0.97-1.04  | 0.547     | 0.323      | -0.002     | 0.99      | 0.95-1.03  | 0.898     | 0.948      |
| Hyperglycemia    | -0.001     | 0.99      | 0.95-1.04  | 0.965     | 0.618      | 0.013      | 1.01      | 0.96-1.06  | 0.590     | 0.396      | 0.010      | 1.01      | 0.96-1.06  | 0.683     | 0.476      | -0.011     | 0.98      | 0.93-1.04  | 0.657     | 0.722      |
| Hyper TG         | -0.002     | 0.99      | 0.94-1.05  | 0.925     | 0.879      | -0.016     | 0.98      | 0.93-1.03  | 0.542     | 0.501      | -0.026     | 0.97      | 0.92-1.02  | 0.328     | 0.304      | 0.043      | 1.04      | 0.98-1.10  | 0.124     | 0.254      |
| Low HDLc         | -0.001     | 0.99      | 0.94-1.05  | 0.958     | 0.709      | -0.007     | 0.99      | 0.94-1.04  | 0.787     | 0.650      | -0.005     | 0.99      | 0.94-1.04  | 0.829     | 0.664      | -0.007     | 0.99      | 0.93-1.04  | 0.785     | 0.348      |
| High Col         | -0.004     | 0.99      | 0.94-1.04  | 0.859     | 0.798      | 0.001      | 1.00      | 0.95-1.05  | 0.952     | 0.824      | -0.001     | 0.99      | 0.94-1.05  | 0.944     | 0.950      | -0.007     | 0.99      | 0.94-1.04  | 0.790     | 0.940      |
| MetS             | -0.013     | 0.98      | 0.94-1.03  | 0.592     | 0.758      | -0.010     | 0.98      | 0.94-1.03  | 0.678     | 0.760      | -0.016     | 0.98      | 0.93-1.03  | 0.500     | 0.552      | -0.003     | 0.99      | 0.94-1.04  | 0.889     | 0.499      |
| Diabetes         | -0.0009    | 0.99      | 0.96-1.03  | 0.961     | 0.663      | 0.003      | 1.00      | 0.96-1.04  | 0.843     | 0.646      | 0.002      | 1.00      | 0.96-1.04  | 0.889     | 0.705      | -0.004     | 0.99      | 0.95-1.03  | 0.839     | 0.976      |

*p < 0.017 were considered as statistically significant (Bonferroni correction). † Admixture adjustment with Monte-Carlo-Markov Chain (k = 3). An additive model was assessed through a logistic regression where risk alleles were interpreted as the unit. Genetic variations in rs9939609 (AA = 2, AT = 1, and TT = 0), rs8050136 (AA = 2, AC = 1, and CC = 0), rs17817449 (GG = 2, GT = 1, and TT = 2) and rs3751723 (TT = 0, GT = 1, and GG = 2), were included as independent variables. Age, sex, and body mass index were included as confounding variables (except for the analysis of body weight excess in which only age and sex were used). An admixture adjustment was performed through a Monte-Carlo-Markov Chain where a three-hybrid genetic stratification was assumed. Abbreviations: Abd. obesity - abdominal obesity, HDLc - high-density lipoprotein cholesterol, HyperTG - hypertriglyceridemia, MetS - metabolic syndrome.
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

In addition to the suspected central regulation of appetite, some authors have described an association of IRX3 expression in adipocyte tissue with energy dissipation (through mitochondrial thermogenesis), and fat storage. This finding suggests that risk alleles in IRX3 might be involved in obesity pathogenesis through several mechanisms and that rs3751723 could be linked to gene expression and adipocyte metabolism. If subjects with this genetic variation show a different expression profile and adipose tissue physiology might be an interesting focus in further researches.

Srivastava et al., reported linkage disequilibrium between both genes in a population from North India. Although a similar phenomenon is thought to be occurring in other groups, the findings from the current study showed no evidence of non-random segregation between the FTO and IRX3 SNPs in this sample of Latin American adults. In this regard, the genetic sub-structure and recent admixture process remain concerning issues that could be interfering with the measurement of inter-gene regulations.

In conclusion, a genetic association between IRX3 and body weight was found in Latin American adults. Furthermore, this relation persisted as statistically significant after an adjustment for sex, age, and genetic ancestry was performed. According to these results, it is plausible that IRX3 gene expression might be involved in obesity prevalence in this population; hence, further studies aimed to describe the role of this gene and its product on energy metabolism seems to be promissory in the understanding of current body weight excess epidemic.

References

1. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014 2014. https://apps.who.int/iris/handle/10665/148114

2. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544. DOI: 10.1016/S0140-6736(16)31012-1

3. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. DOI: 10.1152/physrev.00033.2011

4. Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: A comprehensive review. C R Biol. 2017;340(2):87-108. DOI: 10.1016/j.crvi.2016.11.007

5. Lindstrom S, Loomis S, Turman C, Huang H, Huang J, Aschard H, et al. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS One. 2017;12(3):e0173997. DOI:https://doi.org/10.1371/journal.pone.0173997

6. Wang HJ, Hinney A, Song JY, Scherag A, Meng XR, Grallert H, et al. Association of common variants identified by recent genome-wide association studies with obesity in Chinese children: a case-control study. BMC Med Genet. 2016;17:7. DOI: 10.1186/s12881-016-0268-4

7. Zhao NN, Dong GP, Wu W, Wang JL, Ullah R, Fu JF. FTO gene polymorphisms and obesity risk in Chinese population: a meta-analysis. World J Pediatr. 2019;15(4):382-9. DOI: 10.1007/s12519-019-00254-2

8. Mauer J, Jaffrey SR. FTO, m(6) Am, and the hypothesis of reversible epitranscriptomic mRNA modifications. FEBS Lett. 2018;592(12):2012-22. DOI: 10.1002/1873-3468.13092

9. Akbari ME, Gholamalizadeh M, Doaei S, Mirsafa F. FTO Gene Affects Obesity and Breast Cancer Through Similar Mechanisms: A New Insight into the Molecular Therapeutic Targets. Nutr Cancer. 2018;70(1):30-6. DOI: 10.1080/01635581.2018.1397709

10. Ragvin A, Moro E, Fredman D, Navratilova P, Drivenes O, Engstrom PG, et al. Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci U S A. 2010;107(2):775-80. DOI: 10.1073/pnas.0911591107
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

11. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507(7492):371-5. DOI: 10.1038/nature13138

12. Nowacka-Woszuk J, Prusynska-Oszmalek E, Szypirowski M, Szczerbał I. Nutrition modulates Fto and Ir3 gene transcript levels, but does not alter their DNA methylation profiles in rat white adipose tissues. Gene. 2017;610:44-8. DOI: 10.1016/j.gene.2017.02.002

13. Landgraf K, Scholz M, Kovacs P, Kiess W, Korner A. FTO Obesity Risk Variants Are Linked to Adipocyte IRX3 Expression and BMI of Children - Relevance of FTO Variants to Defend Body Weight in Lean Children? PLoS One. 2016;11(8):e0161739. DOI: 10.1371/journal.pone.0161739

14. Sobalska-Kwapis M, Suchanecka A, Slomka M, Siewierska-Gorska A, Kepka E, Strapagiel D. Genetic association of FTO/IRX region with obesity and overweight in the Polish population. PLoS One. 2017;12(6):e0180295. DOI: 10.1371/journal.pone.0180295

15. Srivastava A, Mittal B, Prakash J, Srivastava P, Srivastava N, Srivastava N. A multianalytical approach to evaluate the association of 55 SNPs in 28 genes with obesity risk in North Indian adults. Am J Hum Biol. 2017;29(2). DOI: 10.1002/ajhb.22923

16. Noguera MC, Schweger A, Gomes V, Briceno I, Alvarez L, Uricoechea D, et al. Colombia’s racial crucible: Y chromosome evidence from six admixed communities in the Department of Bolivar. Ann Hum Biol. 2014;41(5):453-9. DOI: 10.3109/03014460.2013.852244

17. FAO, OMS. Panorama de la Inseguridad Alimentaria y Nutricional en América Latina y el Caribe 2016. Santiago de Chile. 2017. DOI: 10.37777/5789275319727FAO. OMS.

18. Mora-Garcia G, Ruiz-Diaz MS, Espitia-Almeida F, Gomez-Camargo D. Variations in ADIPOR1 But Not ADIPOR2 are Associated With Hypertriglyceridemia and Diabetes in an Admixed Latin American Population. Rev Diabet Stud. 2017;14(2-3):311-28. DOI: 10.1900/RDS.2017.14.311

19. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform. 2012;10(2):117-22. DOI: 10.5808/GI.2012.10.2.117

20. Gómez D. Genetic Structure of Cartagena de Indias Population Using Hypervariable Markers of Y Chromosome. Open Journal of Genetics. 2015; 5(1):15. DOI: 10.4236/ojgen.2015.51003

21. Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8

22. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. DOI: 10.1001/jama.2013.284427

23. Obesity WHOCo, World Health Organization. Division of Noncommunicable D, World Health Organization. Programme of Nutrition F, Reproductive H. Obesity : preventing and managing the global epidemic: report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. Geneva: World Health Organization; 1998. https://apps.who.int/iris/handle/10665/63854

24. Mora GG, Salguedo MG, Ruiz DM, Ramos CE, Alario BA, Fortich A, et al. Concordancia entre cinco definiciones de síndrome metabólico. Cartagena, Colombia. Rev Esp Salud Publica. 2012;86(3):301-11. DOI: 10.1590/S1135-57272012000300009

25. American Diabetes Association. 2 Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13-S27. DOI: 10.2337/dc18-S002

26. Arnold M, Raffler J, Pfeuffer A, Suhre K, Kastenmüller G. SNiPA: an interactive, genetic variant-centered annotation browser. Bioinformatics. 2015;31(8):1334-6.
Interaction analysis of FTO and IRX3 genes with obesity and related metabolic disorders in an admixed Latin American population: a possible risk increases of body weight excess

27. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65. DOI: 10.1039/bi2011779

28. Srivastava A, Mittal B, Prakash J, Srivastava P, Srivastava N, Srivastava N. Association of FTO and IRX3 genetic variants to obesity risk in north India. Ann Hum Biol. 2016;43(5):451-6. DOI: 10.3109/03014460.2015.1103902

29. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.

30. Saldana-Alvarez Y, Salas-Martinez MG, Garcia-Ortiz H, Luckie-Duque A, Garcia-Cardenas G, Vicenteno-Ayala H, et al. Gender-Dependent Association of FTO Polymorphisms with Body Mass Index in Mexicans. PLoS One. 2016;11(1):e0145984. DOI: 10.1371/journal.pone.0145984

31. Caro-Gomez MA, Naranjo-Gonzalez CA, Gallego-Lopera N, Parra-Marin MV, Valencia DM, Arcos EG, et al. Association of Native American ancestry and common variants in ACE, ADIPOR2, MTNR1B, GCK, TCF7L2 and FTO genes with glycemic traits in Colombian population. Gene. 2018;677:198-210. DOI: 10.1016/j.gene.2018.07.066

32. Villalobos-Comparan M, Antuna-Puente B, Villarreal-Molina MT, Canizales-Quinteros S, Velazquez-Cruz R, Leon-Mimila P, et al. Interaction between FTO rs9939609 and the Native American-origin ABCA1 rs9282541 affects BMI in the admixed Mexican population. BMC Med Genet. 2017;18(1):46. DOI: 10.1186/s12881-017-0410-y

33. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6(2):e22. DOI: 10.1371/journal.pmed.1000022

34. Wang T, Heianza Y, Sun D, Huang T, Ma W, Rimm EB, et al. Improving adherence to healthy dietary patterns, genetic risk, and long term weight gain: gene-diet interaction analysis in two prospective cohort studies. BMJ. 2018;360:j5644. DOI: 10.1136/bmj.j5644

35. Ma J, Hennein R, Liu C, Long MT, Hoffmann U, Jacques PF, et al. Improved Diet Quality Associates With Reduction in Liver Fat, Particularly In Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155(1):107-17. DOI: 10.1053/j.gastro.2018.03.038

36. Liu C, Chu C, Zhang J, Wu D, Xu D, Li P, et al. IRX3 is a genetic modifier for birth weight, adolescent obesity and transaminase metabolism. Pediatr Obes. 2018;13(3):141-8. DOI: 10.1111/jpo.12214